GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

How Is Cell Identity Confirmed?

Cell identity is confirmed by combining traceable source records with laboratory tests appropriate to the cell type. For cultured mesenchymal stromal cells (MSCs), these include appearance, a defined surface-marker panel, and differentiation tests. Human cell lines may also need DNA authentication against a reference sample. Viability and contamination tests answer separate questions; a cell count alone cannot establish identity 16923606Download.

General information for adults, not personal medical advice. This article focuses on cells offered for treatment, especially cultured MSCs. Regulatory examples cover the United States and Japan; the cited laboratory criteria are scientific characterization standards, not universal release requirements.

How Is Cell Identity Confirmed?

What Cell Identity Means

Cell identity comes down to a concrete point — which cells sit in the container. Readers need the cell type, the source tissue, whether the cells came from the patient (autologous) or a donor (allogeneic), and how the material was processed. Sharing the “stem cells” label does not make two products the same, and confirmed identity does not by itself establish safety or clinical benefit.

Identity pins down which cells are present. Viability measures how many were alive at the time of testing, while sterility and related checks look for microbes or other contaminants.

A batch can clear one hurdle and miss the next. A viability slip leaves identity and contamination open, and a clean sterility result still leaves the cell type open.

How Records Link a Dose to Its Source

Identity confirmation starts with the paper trail from collection to the final container. The file should link a coded donor or patient identifier to the starting material and document the tissue collected, shipping and storage conditions, processing steps, and final batch number. In the United States, regulators place identity testing inside that broader file, beside microbe testing, purity checks, and strength or activity measures when they fit Download.

If a clinic cannot tell you the tissue source, the steps, and which batch your dose comes from, do not accept lab numbers from a different batch or a different product, because those numbers do not cover your dose.

How Appearance Narrows Identity

The laboratory observes cell shape, attachment, and growth in culture. For cultured human MSCs, the International Society for Cellular Therapy (ISCT) minimum criteria include adherence to plastic under standard culture conditions 16923606.

That visual check cannot stand alone. Fibroblasts and MSCs can look alike and share commonly used markers. A laboratory comparison found that skin and lung fibroblasts expressed several standard MSC markers; some potentially distinguishing markers also changed with repeated culture 20528146. Shape alone therefore cannot establish MSC identity. Unexpected growth needs investigation by the laboratory, not a diagnosis based on appearance alone.

How Surface Markers Help Identify Cells

Laboratories use a panel of markers rather than one positive result. Flow cytometry measures properties of cells passing through a laser beam, including signals used to detect markers on or inside them Flow cytometry. The MSC panel below includes CD-designated markers and HLA-DR; marker names are not all CD numbers. A complete report names each marker tested, the share of positive cells, and the cutoff used.

ISCT Identity Thresholds

The ISCT 2006 position statement on human multipotent mesenchymal stromal cells set three basic laboratory conditions. The cells stick to plastic, display a defined marker pattern, and form bone, fat, and cartilage-forming cells in the dish. The stated thresholds are at least 95% positive for each of CD105, CD73, and CD90, and no more than 2% positive for the exclusion markers CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR 16923606.

These are minimum characterization criteria for culture-expanded human MSCs, not a universal test for every preparation or proof of a repair effect after treatment. In its 2019 nomenclature statement, the ISCT recommended distinguishing stromal cells from cells with demonstrated stem-cell properties. “MSC” should mean “mesenchymal stromal cells” unless the cells truly show self-renewal and tissue-forming power, rather than treating the acronym itself as proof of stemness 31526643. Marker patterns shift with tissue source, culture medium, and time in culture. Without named markers, a stated method, and stated cutoffs, a result has no anchor.

Test Question it answers Typical method
Source and batch records Where did these cells come from, and which batch is this? Donor and collection records, chain-of-custody documents
Appearance and growth Do the cells look and behave as expected? Microscopy, culture observation
Surface-marker profile Which molecular markers do the cells carry? Flow cytometry against a defined marker panel
Differentiation or functional assay Can the cells do what the label implies in the laboratory? Controlled differentiation or activity assays
Genetic authentication Does this human cell culture match its reference source? Short tandem repeat (STR) profiling compared with a reference profile
Chromosome assessment Are large chromosome changes detectable? Karyotype or another suitable chromosome-analysis method; not a substitute for source authentication
Viability What share of cells is alive? Dye-exclusion or equivalent viability assay
Contamination screening Are microbes or endotoxins present? Sterility, mycoplasma, and endotoxin testing

How Function Tests Back the Label

For cultured human MSCs, the ISCT criteria include differentiation toward bone, fat, and cartilage under defined laboratory conditions 16923606. A functional or potency assay may measure a different attribute from identity, depending on the product and its proposed action.

These results do not by themselves establish clinical benefit. Characterization of a cell bank also should not be confused with tests performed on every finished dose.

How Stored Lines Are Authenticated

Short tandem repeat (STR) profiling compares a human cell culture’s DNA pattern with a reference profile to help detect misidentification or human-cell cross-contamination PMC2965362. A matching STR profile supports source authentication; it does not prove MSC differentiation capacity or therapeutic potency. Karyotyping addresses a different question—large chromosome changes—and lacks the same ability to distinguish individual human sources. Neither test replaces contamination screening. The appropriate testing schedule depends on the cell bank and manufacturing process.

Which Tests Do Not Confirm Identity

These companion tests matter for safety, but none of them answers the identity question. A batch report gives every test a separate line with result, method, and date. Viability records how many cells were alive at testing. Sterility screens for bacteria or fungi, and separate mycoplasma and endotoxin tests address organisms or bacterial components that routine sterility testing does not adequately assess. FDA guidance for human somatic cell therapy applications treats identity as one piece of this wider package, next to microbe safety, purity, and strength including potency Download.

Cutoffs vary by product and process. No one passing score covers every preparation Download. Every test stands on its own result and sampling time. With frozen products, the report should spell out whether each result applies before freezing, after thawing, or both.

How to Read the Report for Identity

To confirm identity for your own dose, ask for the full report. At a minimum, the document should list:

  • exact cell type and tissue source, and whether the cells are autologous or allogeneic;
  • processing history, including whether this is a fresh mixture, cultured population, or selected-cell product; a cell-free preparation is not a cell population;
  • marker panel tested, with method and acceptance limits;
  • applicable characterization and functional tests, identifying which concern the source bank and which concern the final batch;
  • viability and contamination results with sampling dates;
  • batch or lot number linking the report to the proposed dose.

Broad phrases carry no weight. “High quality,” “pure stem cells,” or a lone cell count without a counting method leave the cells unidentified. If the preparation is sold as a fresh mixture while the paper behind it studied cultured cells, ask the clinician to explain the gap in writing. That study cannot stand as direct proof for your case. Before interpreting a result, ask staff to show how the report’s batch number links to the proposed container. Then check the sample date, whether testing was before freezing or after thawing, and whether the result concerns that batch or an earlier cell bank. If identifiers differ, request the documented link rather than assuming a match.

Why Identity Alone Does Not Show Benefit

Correctly identified cells still need clinical evidence for the proposed condition, patient group, dose, and route. Laboratory characterization alone cannot establish symptom relief or safety for a particular patient.

Why One Approval Does Not Cover Other Products

On December 18, 2024, the FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone-marrow-derived MSC therapy for steroid-refractory acute graft-versus-host disease in children aged 2 months and older — the first FDA-approved MSC therapy Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. Investigators studied 2 million MSCs per kilogram given intravenously twice weekly for 4 straight weeks 2834381. That U.S. approval concerns this product and indication; it neither approves other MSC preparations nor authenticates another product’s batch. Unapproved regenerative products — from a patient’s own body or a donor’s, including stem cells, stromal vascular fraction, umbilical cord blood products, amniotic fluid, Wharton’s jelly preparations, and exosome products — carry documented risks, and the FDA urges caution about their claims Consumer alert regenerative medicine products including stem cells and exosomesImportant patient and consumer information about regenerative medicine therapies.

Which Regulatory Documents to Check

Neither trial registration nor facility or establishment registration proves approval or lawful marketing. A study listing by itself never shows that a treatment works Important patient and consumer information about regenerative medicine therapies. In Japan, the Act on the Safety of Regenerative Medicine requires obtaining an opinion from a certified committee before submitting the provision plan to the Minister of Health, Labour and Welfare. This plan process is separate from product marketing approval; filing is not proof of clinical effectiveness 001673212.pdf.

Situation Regulatory or trial documents to ask for
Approved product used within its approved indication Approval document matching product, population, and use
Investigational intervention under supervised trial conditions Trial protocol, oversight, and consent documents
Clinic service provided under a filed plan Documents establishing filing status, without treating filing as proof of effectiveness

These documents establish regulatory or study status, not laboratory identity. Batch-linked identity results are still a separate request.

Which Identity Questions to Ask

An illustrative example, not a patient case: a brochure advertises a fresh fat-derived mixture while its paper covers cultured cells with ISCT-style marker data. Readers can place the source and processing lines side by side, then ask the clinician where the gap comes from and which identity tests cover the actual product on offer rather than the published cells.

If a brochure calls an acellular product “stem cells,” ask what the preparation actually contains. A cell-free product needs its own composition and quality evidence; a viable-cell count or MSC marker panel cannot describe a population that is not present.

Once those identity questions are answered, separate them from benefit questions. Which human studies back this exact preparation and use — who took part, what was measured, what was the comparison, how long was follow-up, and what side effects appeared? Who made and handled the cells? Who manages complications, and what does follow-up include?

Put the answers in writing. When papers go missing, evidence comes from another cell type, dose, or route, or staff press for a quick decision, take it as a warning sign. Step back and seek an independent medical opinion.

If you are comparing batch reports or treatment plans, you can send your questions to the patient support team and ask about appointment coordination.

Contact the Support Team

The Short Answer

Cell identity is confirmed through traceable records and cell-type-specific laboratory evidence—not a cell count or a “stem cell” label. For cultured human MSCs, ask about marker profiles and differentiation criteria; for human cell lines, ask how any STR result was matched to a reference. Keep identity, viability, contamination, and clinical benefit as separate questions.

References

  1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. https://pubmed.ncbi.nlm.nih.gov/16923606/
  2. U.S. Food and Drug Administration. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). https://www.fda.gov/media/73624/download
  3. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 2011;20(1):53-66. https://pubmed.ncbi.nlm.nih.gov/20528146/
  4. National Cancer Institute. NCI Dictionary of Cancer Terms — flow cytometry. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/flow-cytometry
  5. Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019-1024. https://pubmed.ncbi.nlm.nih.gov/31526643/
  6. Barallon R, Bauer SR, Butler J, et al. Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. In Vitro Cell Dev Biol Anim. 2010;46(9):727-732. https://pmc.ncbi.nlm.nih.gov/articles/PMC2965362/
  7. U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease (press announcement, December 18, 2024). https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host
  8. JAMA. Remestemcel-L-rknd for Steroid-Refractory Acute Graft-vs-Host Disease in Pediatric Patients. https://jamanetwork.com/journals/jama/fullarticle/2834381
  9. U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
  10. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
  11. Ministry of Health, Labour and Welfare, Japan. Notice to medical institutions providing regenerative medicine under the Act on the Safety of Regenerative Medicine. March 12, 2026. https://www.mhlw.go.jp/content/10800000/001673212.pdf